<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03536845</url>
  </required_header>
  <id_info>
    <org_study_id>E-17-2425</org_study_id>
    <nct_id>NCT03536845</nct_id>
  </id_info>
  <brief_title>Vitamin D Supplementation to Prevent Vitamin D Deficiency for Children With Epilepsy</brief_title>
  <official_title>Vitamin D Supplementation to Prevent Vitamin D Deficiency for Children With Epilepsy: a Randomized Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King Saud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dallah hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>King Saud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the maintenance dose of vitamin D supplementation required for children with
      epilepsy to maintain normal vitamin D level.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      children aged 2-16 years diagnosed with idiopathic epilepsy will be randomized to receive
      either cholecalciferol doses (400IU vs 1000IU) with follow up at 3 and 6 months post
      supplementation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">January 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vitamin D level &lt; 75 nmol/L</measure>
    <time_frame>6 months of supplementation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seizure rate</measure>
    <time_frame>6 months of supplementation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bone mineral density (BMD) measurement</measure>
    <time_frame>6 months of supplementation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost- effectiveness of vitamin D supplementation</measure>
    <time_frame>6 months of supplementation</time_frame>
    <description>cost of vitamin D supplementation compared to the cost of poor bone health, hospital admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Prevalence of hypercalcemia total calcium &gt;2.7mg/dl, 25 OH vit D level&gt; 250 nmol/l, and Urine calcium: creatinine ration &gt; 1.2 mol/mol, or &gt; 0.41g/g.</measure>
    <time_frame>6 months of supplementation</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Vitamin D level &lt; 75 nmol/L</measure>
    <time_frame>6 months of supplementation</time_frame>
    <description>subgroup analysis among enzyme inducer and non-enzyme inducer (anti-epileptic medications) AEDs</description>
  </other_outcome>
  <other_outcome>
    <measure>Vitamin D level &lt; 75 nmol/L</measure>
    <time_frame>6 months of supplementation</time_frame>
    <description>subgroup analysis among obese and non-obese patients</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">203</enrollment>
  <condition>Epilepsy</condition>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>400 IU</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>1000 IU</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D 3</intervention_name>
    <description>oral drops</description>
    <arm_group_label>400 IU</arm_group_label>
    <arm_group_label>1000 IU</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Children aged between 2-16 years who were diagnosed with Epilepsy and being treated
             with AEDs

          2. Followed up in the outpatient pediatric neurology clinic at King Khalid University
             Hospital during the period of two years.

        Exclusion Criteria:

          1. Children with pre-existing vitamin D metabolism problems; because they are known to
             need different vitamin D doses and monitoring for clinical improvement:

               -  Vitamin D dependent rickets

               -  Malabsorption syndromes like celiac disease, inflammatory bowel disease

               -  Renal disease

               -  Hepatic disease

          2. Children who are not safe to start vitamin D supplementation; because vitamin D
             supplementation will causes toxicity and induces nephrocalcinosis:

               -  Hypercalcemia at baseline total corrected calcium &gt;2.5mg/dl

               -  Vitamin D level &gt; 250 nmol/L

               -  Urine calcium: creatinine ration &gt; 1.2 mol/mol, or &gt; 0.41g/g.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reem Al Khalifah</last_name>
    <role>Principal Investigator</role>
    <affiliation>King Saud University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reem Al Khalifah, MBBS, FRCps, Msc</last_name>
    <phone>+96655710303</phone>
    <email>ralkahlifah@ksu.edu.sa</email>
  </overall_contact>
  <location>
    <facility>
      <name>Reem ALKhalifah</name>
      <address>
        <city>Riyadh</city>
        <zip>3134-13217</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reem ALKhalifah, MBBS</last_name>
      <phone>114690756</phone>
      <email>ralkhalifah@ksu.edu.sa</email>
    </contact>
    <investigator>
      <last_name>Fahad Bashiri, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2018</study_first_submitted>
  <study_first_submitted_qc>May 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2018</study_first_posted>
  <last_update_submitted>May 23, 2018</last_update_submitted>
  <last_update_submitted_qc>May 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>King Saud University</investigator_affiliation>
    <investigator_full_name>Reem Al Khalifah</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

